Founded in 2018, Alamar Biosciences focuses on overcoming the sensitivity limitations of conventional protein assays to advance biomarker discovery and translational research. The company's core offerings include the ARGO HT System, a fully automated precision proteomics instrument, and NULISA technology, which utilizes nucleic acid-linked immuno-sandwich assays for multiplexed protein analysis. Operating globally with a direct sales presence in North America, Europe, and China, Alamar generates revenue through a razor/razor-blade business model driven by instrument placements and recurring consumable sales. Its platforms are utilized across various research areas, including immunology, neurology, and oncology, supporting the development of clinical diagnostics. The company's products are currently labeled for research use only and are adopted by top biopharmaceutical companies and research institutions worldwide.
